Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Dutch supplier Bedrocan has become the world’s first producer of medicinal cannabis to be compliant with the European Medicines Agency’s good manufacturing practice (GMP) standards. 24 January 2017
Marinus Pharmaceuticals saw its shares surge as much as 49% after it announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase II open-label study evaluating its CNS-selective GABAA modulator. 24 January 2017
Biogen’s $1.25 billion agreement to license Forward Pharma’s intellectual property was a clear boon for the Copenhagen, Denmark-based company, whose shares rose a stunning 55% in morning trade on Tuesday. 22 January 2017
Belgian drugmaker UCB has filed a supplemental New Drug Application (sNDA) with the US Food and Drug Administration to extend the label for epilepsy drug Briviact (brivaracetam). 20 January 2017
Takeda, a company with around 30,000 employees and $16 billion in annual revenue, is forging a strategic alliance with tiny New York-based biotech Ovid Therapeutics. 19 January 2017
UK-headquartered Mallinckrodt has reached a $100 million settlement over a Federal Trade Commission complaint that it violated antitrust laws. 19 January 2017
Forward Pharma has entered into a binding agreement with two wholly-owned subsidiaries of Biogen on a settlement and license agreement. 17 January 2017
Shares of Israeli pharma firm Alcobra (Nasdaq: ADHD) went into free fall in pre-market US trading today, after it reported disappointing top-line results from MEASURE. 17 January 2017
Irish life sciences company Malin Corp says it has acquired a 33% shareholding of Wren Therapeutics, a newly-created biotechnology company based in Cambridge, UK. 17 January 2017
Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 separate therapeutic indications, treating conditions ranging from overactive bladder to chronic migraines. 16 January 2017
The use of benzodiazepines and benzodiazepine-like drugs increased the risk of stroke among people with Alzheimer’s disease by 20%, shows a study from the University of Eastern Finland. 16 January 2017
The Japanese drugmakers Eisai and Chugai Pharmaceutical have agreed to a deal under which Eisai will acquire the rights to manufacture flunitrazepam and to market the drug in Japan as Rohypnol. 16 January 2017
A Phase II/III study (SEP360-221), the first of two planned pivotal studies, evaluating the novel drug candidate dasotraline in adults aged 18 to 55 years with moderate to severe binge eating disorder (BED) met the primary efficacy endpoint as well as all key secondary efficacy endpoints. 16 January 2017
Indian drugmaker Cadila Healthcare and its US subsidiary today announced that they have finalized an agreement with privately-held US generics firm Upsher-Smith Laboratories, to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules. 13 January 2017
Zambon, a privately-owned pharmaceutical company based in Italy, has entered into a long-term agreement with flu-vaccine specialists Seqirus to commercialize Xadago (safinamide) in Australia and New Zealand. 11 January 2017
In an expert view piece, Todd Feaster, clinical program manager for dementia with leading clinical trial technology and specialty services provider Bracket, employs his Alzheimer’s disease expertise to comment on the trial environment in this most challenging therapeutic area. 11 January 2017
Dublin-headquartered Allergan has purchased an option to acquire Lysosomal Therapeutics (LTI), a privately owned small molecule specialist based in the USA, which is focused on developing novel therapies against neurodegenerative diseases. 10 January 2017